Good Health Can’t Wait.

Corporate Overview Annual Report 2014 - 15
Strategy for
Valganciclovir
Estimates show that congenital (present
at birth) CMV infection affects one in 150
children in the US. In adults, Valganciclovir
is used to treat CMV retinitis (eye infection
that can cause blindness) in people
who have acquired immunodeficiency
syndrome (AIDS), and in people who
have received an organ transplant (heart,
kidney or kidney-pancreas).
In the pediatric population, Valganciclovir
is used for the prevention of CMV disease
in patients with kidney or heart transplant.
Valganciclovir is in a class of medications
called antivirals. It works by preventing
the spread of CMV disease or slowing the
growth of CMV.
We decided to bring this much-needed
therapy to address this disease by
accelerating the availability of an
affordable option in this critical antiviral
segment.
We pieced together a strategy for the
product and more importantly built
predictability into the launch timeline.
Using information available in the public
domain, information about the API Supply
Chain, an IP strategy and litigation, we
were able to launch the product ahead of
all the others.
Working closely with
various cross-functional
teams, such as R&D,
Regulatory API and
Manufacturing across
geographies, we were able
to successfully navigate the
legal requirements and launch
the product in an accelerated
time frame.
That day we broke a boundary. Not just
for our Company, but for the industry as
a whole. We created a new pathway to
the patient, one that is more affordable,
equally high quality and just as
effective.
We overcame the skepticism
of peers to meet a huge
unmet need. Our supply
chain management teams
ensured the complex drug
was available on shelf within
a short period of approval.
Since its launch in December
2014, nearly 40% of patients
in the US are now using
Dr. Reddy’s Valganciclovir
and today we still remain an
affordable option in bringing this
critical medicine to patients.
Built predictability into the launch timeline
Used information available in the public
domain and the API supply chain
Created an IP strategy
Launched product
ahead of all others
Children and adults
can now look forward
to an affordable option
for the treatment of
CMV. This encourages
us to continue to seek
new ways to make
expensive medication
affordable and improve
patients’ lives.
11